Thanks to the Pfizer/BioNTech and Moderna COVID-19 vaccines, it is likely you have heard the term mRNA. However, it is unlikely you have heard it in the context in which Anima Biotech is exploring this space. Anima is developing Translation Control Therapeutics, which takes a novel approach to discover small molecules that can selectively control mRNA translation in order to treat diseases with previously undruggable proteins or hard targets.